236 related articles for article (PubMed ID: 31496361)
1. An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan.
Kogushi K; Ogawa T; Ikeda S
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):455-471. PubMed ID: 31496361
[No Abstract] [Full Text] [Related]
2. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
3. Determinants of orphan drugs prices in France: a regression analysis.
Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
[TBL] [Abstract][Full Text] [Related]
4. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
5. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
[TBL] [Abstract][Full Text] [Related]
6. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
Kawakami A; Masamune K
Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
[TBL] [Abstract][Full Text] [Related]
7. The implementation of health technology assessment principles in public decisions concerning orphan drugs.
Brenna E; Polistena B; Spandonaro F
Eur J Clin Pharmacol; 2020 Jun; 76(6):755-764. PubMed ID: 32219539
[TBL] [Abstract][Full Text] [Related]
8. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
9. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
[No Abstract] [Full Text] [Related]
10. Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia X; Gil A; Poveda-Andrés JL; Shepherd J; Tort M
Farm Hosp; 2019 Jul; 43(4):121-127. PubMed ID: 31276443
[TBL] [Abstract][Full Text] [Related]
11. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
12. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
Adkins EM; Nicholson L; Floyd D; Ratcliffe M; Chevrou-Severac H
Clinicoecon Outcomes Res; 2017; 9():327-342. PubMed ID: 28652787
[TBL] [Abstract][Full Text] [Related]
13. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
McCormick JI; Berescu LD; Tadros N
Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries.
Jakubowski S; Kawalec P; Holko P; Kowalska-Bobko I; Kamusheva M; Petrova G; Draganić P; Fuksa L; Männik A; Ispán F; Briedis V; Bianchi I; Paveliu MS; Tesar T
Front Pharmacol; 2024; 15():1369178. PubMed ID: 38523639
[No Abstract] [Full Text] [Related]
15. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
16. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
[TBL] [Abstract][Full Text] [Related]
17. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
18. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
Menon D; Clark D; Stafinski T
Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
[TBL] [Abstract][Full Text] [Related]
19. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
Fontrier AM
Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
[TBL] [Abstract][Full Text] [Related]
20. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
Danzon PM
Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]